Printer Friendly

US Medical Innovations Granted Japanese Patent for Canady Hybrid Plasma Technology.

M2 PHARMA-February 10, 2016-US Medical Innovations Granted Japanese Patent for Canady Hybrid Plasma Technology


- The Japanese Patent Office (JPO) decision to grant US biomedical device specification manufacturing company US Medical Innovations' patent for the Canady Hybrid Plasma (CHP) technology, the company said.

CHP simultaneously cuts and coagulates biological tissue, and is the primary intellectual property behind the Canady Hybrid Plasma Scalpel (CHPS), a revolutionary device now beginning to secure a strong initial foothold in the US surgical market.

This approval by the JPO represents an important milestone for the company's pending plans for international distribution.

The US FDA-registered CHPS is a smart multi-functional electrosurgical handpiece, which delivers a precise beam less than 1.0mm in diameter and a depth of injury as low as 0.1mm.

US Medical Innovations said that the technology behind the CHPS decreases tissue damage, perioperative blood loss, operative time, blood transfusion rates, and helps surgeons perform total knee replacements without the use of a tourniquet.

The CHPS incorporates four separate operating modes: hybrid plasma, argon plasma coagulation, conventional monopolar cut and coagulation, which can be used in a range of subspecialties, such as cardiovascular surgery, endoscopy, ENT, general surgery, gynecology, neurosurgery, orthopedics, plastics, surgical oncology, thoracic surgery and dermatology.

US Medical Innovations is a private FDA registered US biomedical device specification manufacturing company founded by surgeon and inventor, Jerome Canady, M.D. USMI's focus is developing advanced, innovative and affordable plasma electrosurgical devices.

USMI's products are designed for ambulatory and inpatient endoscopy centers as well as complex surgical procedures.

US Patent Innovations, LLC, USMI's parent company, is a private investor-owned US company founded by Jerome Canady, M.D. USPI has over 120 partners, whose main focus is to invest in new and innovative technologies in the fields of electrosurgery, plasma medicine and surgical devices.

((Comments on this story may be sent to

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 10, 2016
Previous Article:Catalent posts lower net earnings of USD30.7m for Q2 2016.
Next Article:Lemoine Named to Insulet Board of Directors.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |